Jenscare Scientific-B (09877): 6-month follow-up results of LuX-Valve Plus clinical study TRAVEL III and 2-year follow-up results of TRAVEL II released at TCT 2026 in the United States

Zhitong Finance APP News, Jenscare Scientific-B (09877) announced that recently, the 6-month follow-up results of the multicenter randomized controlled clinical trial (TRAVEL III) and the 2-year long-term follow-up results of the multicenter clinical trial (TRAVEL II) of the LuX-Valve Plus transcatheter tricuspid valve intervention replacement system were released at the 2026 Transcatheter Cardiovascular Therapeutics conference (TCT 2026), demonstrating that the Company's product has excellent performance in safety, efficacy, and durability, and is expected to meet a broad range of unmet clinical needs.